Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials

Natori, Akina; Ethier, Josee-Lyne; Amir, Eitan; Cescon, David W.

doi:10.1016/j.ejca.2017.02.024

Cited by 55 publications

(41 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As expected, most patients receiving NAT did not go on to receive AT given the lack of available options at the time. With new evidence to support the use of adjuvant capecitabine among patients with residual TNBC post-NAT, 39 an increase in the use of NAT and postoperative capecitabine is expected. 40,41 A remarkable 80% of patients with stage I-III TNBC in our study received RT.…”

Section: Treatmentmentioning

confidence: 99%

A population‐based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple‐negative breast cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Treatmentmentioning

confidence: 99%

A population‐based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple‐negative breast cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“… 54 A meta-analysis also provided a rationale for adding capecitabine to either neoadjuvant or adjuvant standard chemotherapy in patients with TNBC. 55 Despite its substantial toxicity, additional capecitabine might be a reasonable option for patients with TNBC carrying a higher risk of relapse. Furthermore, in these patients, postneoadjuvant trials based on actionable molecular targets identified from residual tumour tissues should also be considered.…”

Section: Current Treatment Options In Early Tnbcmentioning

confidence: 99%

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies

2018

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is a long-lasting orphan disease in terms of little therapeutic progress during the past several decades and still the standard of care remains chemotherapy. Experimental discovery of molecular signatures including the ‘BRCAness’ highlighted the innate heterogeneity of TNBC, generating the diversity of TNBC phenotypes. As it contributes to enhancing genomic instability, it has widened the therapeutic spectrum of TNBC. In particular, unusual sensitivity to DNA damaging agents was denoted in patients with BRCA deficiency, suggesting therapeutic benefit from platinum and poly(ADP-ribose) polymerase inhibitors. However, regardless of enriched chemosensitivity and immunogenicity, majority of patients with TNBC still suffer from dismal clinical outcomes including early relapse and metastatic spread. Therefore, efforts into more precise and personalised treatment are critical at this point. Accordingly, the advance of multiomics has revealed novel actionable targets including PI3K-Akt-mTOR and epidermal growth factor receptor signalling pathways, which might actively participate in modulating the chemosensitivity and immune system. Also, TNBC has long been considered a potential protagonist of immunotherapy in breast cancer, supported by abundant tumour-infiltrating lymphocytes and heterogeneous tumour microenvironment. Despite that, earlier studies showed somewhat unsatisfactory results of monotherapy with immune-checkpoint inhibitors, consistently durable responses in responders were noteworthy. Based on these results, further combinatorial trials either with other chemotherapy or targeted agents are underway. Incorporating immune-molecular targets into combination as well as refining the standard chemotherapy might be the key to unlock the future of TNBC. In this review, we share the current and upcoming treatment options of TNBC in the framework of scientific and clinical data, especially focusing on early stage of TNBC.

show abstract

“…These suggest improved outcomes in survival in breast cancer patients. All the patients with poor prognostic variables like triple negative, Er negative, HER2 positive tumors, those with axillary node positivity, high Ki67, vascular invasions, lymphatic invasions, perineural invasions and perinodal extensions showed better survival [35].…”

Section: Discussionmentioning

confidence: 96%

Efficacy of Jackfruit365™ Green Jackfruit Flour Fortified Diet on Pegfilgrastim to Prevent Chemotherapy-Induced Leukopenia, Irrespective of Tumor Type or Drugs Used—A Retrospective Study

Varughese¹,

Joseph²,

Menon

2020

Biomolecules

View full text Add to dashboard Cite

Chemotherapy-Induced Leukopenia (CIL) is associated with increased mortality and economic burden on patients. This study was conducted to evaluate whether inclusion of green jackfruit flour in regular diet of those patients receiving chemotherapy, could prevent CIL. This was a retrospective study conducted among a group of patients undergoing chemotherapy for solid tumors at Renai Medicity Hospital, Palarivattom, Cochin, Kerala, India, since June 2018. The study group comprised of 50 consecutive subjects, who were supplemented with green jackfruit flour diet in their regular diet and further followed up prospectively. The control group was retrospective with 50 subjects prior to June 2018, with no diet supplements. Those who received less than three cycles were excluded from either arm. The mean age of the participants in study group and control group were 53.16 ± 11.06 and 56.96 ± 12.16 years respectively. In the study group, six patients out of 37, and 20 patients out of 50 in the control group, developed CIL. They received 38 and 105 vials of filgrastim respectively. After excluding those cycles in study group patients, where green jackfruit flour was not taken, the mean number of cycles in which CIL developed (p = 0.00) and number of vials of filgrastim taken per cycle (p = 0.00) were significantly different from control group and no patient in the study group developed CIL. Inclusion of green jackfruit flour as a dietary intervention prevents chemotherapy-induced leukopenia in patients undergoing chemotherapy along with pegfilgrastim.

show abstract

Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials

Cited by 55 publications

References 39 publications

A population‐based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple‐negative breast cancer

A population‐based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple‐negative breast cancer

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies

Efficacy of Jackfruit365™ Green Jackfruit Flour Fortified Diet on Pegfilgrastim to Prevent Chemotherapy-Induced Leukopenia, Irrespective of Tumor Type or Drugs Used—A Retrospective Study

Contact Info

Product

Resources

About